Fri, Jul 25, 2014, 7:34 AM EDT - U.S. Markets open in 1 hr 56 mins

Recent

% | $
Click the to save as a favorite.

Sarepta Therapeutics, Inc. Message Board

  • cbdanielson@sbcglobal.net cbdanielson Jan 17, 2013 10:38 AM Flag

    Wedbush

    As per Rosenblum tweet, Wedbush thinks SRPT is worth $60 even without AA.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Look at this way... From a share price perspective, as long as it gets approved, it doesn't so much matter whether it's on time, or whether it's early, the current share price is an insane discount either way, as the market seems intent on punishing the stock because it hasn't already received early approval, which is ridiculous.

      In fact, after the big day, shorts started crowing "nice results, but if it doesn't get early approval, $45 is not justified."

      Phooey! I say.

      Before those results came, were longs in this stock for early approval?

      No!

      Longs were in it for results. And we got great results in the amount of boys tested. I contend the whole early approval hoopla was more or less promoted by shorts as a way to attack the stock.

      The current share price should be $45 imo based on results. Early approval or not.

      From a parent and patient perspective, hopefully the good people at the FDA get this approved ASAP.

      There better be NO PROTECTIONISM of any competitors. And surely any delay could be viewed by some people as accessory to something.... You can fill in your own something.

 
SRPT
20.63-0.72(-3.37%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.